Safety and tolerance after intravenous administration of 0.3 mmol/kg Gd-DTPA. Results of a randomized, controlled clinical trial.
Niendorf
H P
HP
Clinical Research Diagnostics, Schering AG, Berlin, Germany.
Haustein
J
J
Louton
T
T
Beck
W
W
Laniado
M
M
D003287:Contrast Media / Q000008:administration & dosage / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D004361:Drug Tolerance; D005682:Gadolinium / Q000008:administration & dosage / Q000009:adverse effects*; D019786:Gadolinium DTPA; D005858:Germany; D006801:Humans; D007262:Infusions, Intravenous; D008279:Magnetic Resonance Imaging / Q000379:methods; D009942:Organometallic Compounds / Q000008:administration & dosage / Q000009:adverse effects*; D004369:Pentetic Acid / Q000008:administration & dosage / Q000009:adverse effects*; D016037:Single-Blind Method
D003287:Contrast Media; D009942:Organometallic Compounds; D004369:Pentetic Acid; D005682:Gadolinium; D019786:Gadolinium DTPA